


BIOTECHNOLOGY IN MEDICAL SCIENCES



Firdos Alam Khan



CRC Press
Taylor & Francis Group

**BIOTECHNOLOGY
IN
MEDICAL SCIENCES**

BIOTECHNOLOGY IN MEDICAL SCIENCES

Firdos Alam Khan

Manipal University

Dubai, UAE



CRC Press

Taylor & Francis Group

Boca Raton London New York

CRC Press is an imprint of the
Taylor & Francis Group, an **informa** business

CRC Press
Taylor & Francis Group
6000 Broken Sound Parkway NW, Suite 300
Boca Raton, FL 33487-2742

© 2014 by Taylor & Francis Group, LLC
CRC Press is an imprint of Taylor & Francis Group, an Informa business

No claim to original U.S. Government works
Version Date: 20140425

International Standard Book Number-13: 978-1-4822-2368-2 (eBook - PDF)

This book contains information obtained from authentic and highly regarded sources. Reasonable efforts have been made to publish reliable data and information, but the author and publisher cannot assume responsibility for the validity of all materials or the consequences of their use. The authors and publishers have attempted to trace the copyright holders of all material reproduced in this publication and apologize to copyright holders if permission to publish in this form has not been obtained. If any copyright material has not been acknowledged please write and let us know so we may rectify in any future reprint.

Except as permitted under U.S. Copyright Law, no part of this book may be reprinted, reproduced, transmitted, or utilized in any form by any electronic, mechanical, or other means, now known or hereafter invented, including photocopying, microfilming, and recording, or in any information storage or retrieval system, without written permission from the publishers.

For permission to photocopy or use material electronically from this work, please access www.copyright.com (<http://www.copyright.com/>) or contact the Copyright Clearance Center, Inc. (CCC), 222 Rosewood Drive, Danvers, MA 01923, 978-750-8400. CCC is a not-for-profit organization that provides licenses and registration for a variety of users. For organizations that have been granted a photocopy license by the CCC, a separate system of payment has been arranged.

Trademark Notice: Product or corporate names may be trademarks or registered trademarks, and are used only for identification and explanation without intent to infringe.

Visit the Taylor & Francis Web site at
<http://www.taylorandfrancis.com>

and the CRC Press Web site at
<http://www.crcpress.com>

Contents

Preface.....	xxi
Acknowledgments.....	xxiii
Author.....	xxv
Chapter 1 Introduction to biotechnology in medical sciences.....	1
1.1 Introduction.....	1
1.2 What is biotechnology all about?.....	1
1.3 Medical products developed by using biotechnology tools.....	3
1.3.1 Antibiotics.....	3
1.3.2 Recombinant insulin.....	4
1.3.3 Vaccines.....	5
1.3.4 Monoclonal antibodies.....	6
1.3.5 Bioengineered tissues.....	7
1.3.6 Adult stem cell therapy.....	8
1.4 Emerging trends.....	9
1.4.1 Embryonic stem cells.....	9
1.4.2 Human genome project.....	11
1.4.2.1 Significance of the genome project.....	12
1.4.3 RNA interference technology.....	12
1.4.4 Phage therapy.....	13
1.4.5 Recombinant DNA technology.....	13
1.4.6 Biochips.....	14
1.4.7 Gene therapy.....	14
1.4.8 Liposome-based drug delivery.....	14
1.4.9 Bionanotechnology.....	14
1.5 Summary.....	15
1.6 Scholar's achievement.....	16
1.7 Knowledge builder.....	17
Further reading.....	18
Chapter 2 Human diseases: Causes and reasons.....	23
2.1 Introduction.....	23
2.2 Human disease.....	23
2.2.1 Infection.....	23
2.2.2 Illness.....	24
2.2.3 Disorder.....	24
2.2.4 Medical condition.....	24

2.2.5	Morbidity	25
2.2.6	Other classifications	25
2.3	Classification of diseases	25
2.3.1	Infectious diseases.....	26
2.3.1.1	Bacterial diseases	26
2.3.1.2	Parasitic diseases.....	27
2.3.1.3	Viral diseases.....	28
2.3.2	Noninfectious diseases.....	29
2.3.2.1	Necrosis.....	30
2.3.2.2	Apoptosis	31
2.3.2.3	Nutritional deficiency diseases.....	33
2.4	Genetic diseases.....	34
2.4.1	Single-gene disorder	34
2.4.1.1	Autosomal dominant disorder	34
2.4.1.2	Autosomal recessive disorder	34
2.4.1.3	X-linked dominant disorder.....	35
2.4.1.4	X-linked recessive disorder	35
2.4.1.5	Y-linked disorder	36
2.4.1.6	Multifactorial disorder.....	36
2.4.2	Chromosomal abnormalities	36
2.4.3	Mitochondrial disorders.....	37
2.5	Autoimmune disease	37
2.6	Disease transmission	38
2.6.1	Transmission through droplet contact	38
2.6.2	Fecal–oral transmission	40
2.6.3	Sexual transmission	40
2.7	Epidemiology of diseases	40
2.8	Diseases diagnosis.....	40
2.8.1	Types of diagnosis tests	41
2.8.1.1	Invasive tests.....	41
2.8.1.2	Noninvasive tests.....	41
2.8.1.3	Minimal invasive tests	42
2.8.2	Diagnostic laboratories	42
2.8.2.1	Pathology laboratory	42
2.8.2.2	Radiology laboratory.....	42
2.8.2.3	Nuclear medicine laboratory.....	42
2.8.2.4	Clinical neurophysiology laboratory	43
2.9	Diagnostics tools.....	43
2.9.1	Molecular tools.....	43
2.9.1.1	Polymerase chain reaction technique	43
2.9.1.2	Restriction fragment-length polymorphism analysis	45
2.9.1.3	Reverse transcription-PCR.....	45
2.9.1.4	Single-strand conformation polymorphism-PCR.....	46
2.9.1.5	Ligase chain reaction.....	46
2.9.1.6	Microarray analysis.....	47
2.9.1.7	Fluorescence <i>in situ</i> hybridization technique	47
2.9.2	Biochemical techniques	48
2.9.2.1	Blood analyzer.....	48
2.9.2.2	Enzyme-linked immunosorbent assay.....	49

2.9.3	Histopathology.....	49
2.9.3.1	Immunohistochemistry	49
2.10	Current challenges of human diseases	50
2.11	Summary	50
2.12	Knowledge builder	51
	Further reading	52
Chapter 3	Bacteriology and antibiotics	59
3.1	Introduction.....	59
3.2	Microorganism: Historical perspective.....	59
3.3	Classification of microorganisms.....	59
3.4	Organization of bacteria.....	60
3.4.1	Structure of bacterium.....	60
3.4.1.1	Intracellular structures	62
3.4.1.2	Extracellular structures.....	62
3.4.2	Bacterial genetics	62
3.4.3	Nomenclature of bacteria	63
3.4.4	Bacteria: Friends or foes.....	63
3.4.4.1	Parasitism.....	63
3.4.4.2	Mutualism.....	64
3.4.4.3	Commensalism	64
3.4.5	Pathogenic bacteria.....	64
3.5	Applications of microbes.....	65
3.5.1	Antimicrobial drugs.....	65
3.5.1.1	Classification of antibiotics.....	65
3.5.2	Antibiotic production.....	66
3.5.2.1	Penicillin production.....	67
3.5.2.2	Cephalosporin production	68
3.5.2.3	Streptomycin production.....	68
3.5.2.4	Synthesis of vitamin B12 using microbes.....	69
3.5.2.5	Production of enzymes by using microbes.....	69
3.6	Microbial biotransformation.....	69
3.6.1	Biotransformation of D-sorbitol to L-sorbose.....	70
3.6.2	Biotransformation of antibiotics.....	70
3.6.3	Biotransformation of steroids	71
3.7	Food microbiology.....	71
3.7.1	Food pathogens.....	71
3.7.2	Problems of food pathogens	72
3.8	Challenges of treating microbial infections	72
3.8.1	Mechanism of drug resistance.....	74
3.8.2	Drug-resistant microorganisms.....	74
3.8.2.1	<i>Staphylococcus aureus</i>	74
3.8.2.2	<i>Streptococcus pyogenes</i> and <i>Streptococcus pneumoniae</i>	74
3.8.2.3	<i>Pseudomonas aeruginosa</i>	75
3.8.2.4	<i>Clostridium difficile</i>	75
3.8.2.5	<i>Salmonella</i> and <i>E. coli</i>	75
3.8.3	Solution for drug-resistant microorganisms	75
3.9	Summary	75
3.10	Scholar's achievements	76

3.11	Knowledge builder	77
	Further reading	78
Chapter 4	Virology and vaccines.....	83
4.1	Introduction.....	83
4.2	Discovery of viruses.....	83
4.3	Anatomy of virus.....	84
4.3.1	Helical-shaped viruses	84
4.3.2	Icosahedral-shaped viruses	85
4.3.3	Enveloped viruses	85
4.3.4	Complex viruses	86
4.4	Internal organization of viruses.....	86
4.5	Human diseases caused by viruses.....	87
4.5.1	Epidemiology of viral-induced diseases.....	88
4.5.2	Epidemic caused by viruses.....	89
4.5.3	Pandemic caused by viruses.....	89
4.5.4	Oncovirus	89
4.5.5	Avian flu.....	91
4.5.5.1	How to diagnosis viral infection.....	92
4.6	Prevention strategy for viral infections.....	92
4.7	Antiviral drugs	93
4.7.1	Targeting cell surface	93
4.7.2	Entry inhibitor.....	94
4.7.3	Uncoating inhibitor	94
4.7.4	Viral synthesis.....	94
4.7.5	Integrase.....	94
4.7.6	Translation or ribozymes.....	95
4.7.7	Protease inhibitors.....	95
4.7.8	Challenges of antiviral drugs	95
4.8	Significance of vaccines	95
4.8.1	Type of vaccines	96
4.8.1.1	Live attenuated vaccines.....	96
4.8.1.2	Inactivated vaccines.....	96
4.8.1.3	Toxoid vaccines	96
4.8.1.4	Component vaccines.....	96
4.8.1.5	Other vaccines	97
4.8.2	Production of vaccines.....	97
4.8.3	Delivery of vaccines	98
4.9	Vaccines controversies	98
4.9.1	Effectiveness of vaccines.....	98
4.9.2	Safety of vaccines.....	99
4.9.2.1	Vaccine overdose.....	99
4.10	Development of new vaccines	99
4.10.1	Vaccine against rotavirus	100
4.10.2	Vaccine against pneumococcal disease.....	100
4.10.3	Human papillomavirus	101
4.10.4	Meningococcal meningitis A	101
4.11	Summary	102
4.12	Scholar's achievements	102

4.13	Knowledge builder	103
	Further reading	105
Chapter 5	Immunological disorders and immunotherapy	109
5.1	Introduction.....	109
5.2	Immune system.....	109
5.3	Classification of immune system.....	109
5.3.1	Innate immune system	109
5.3.1.1	Physical barrier.....	110
5.3.2	Cellular network of innate immune system	111
5.3.2.1	Mast cells.....	112
5.3.2.2	Phagocytes	112
5.3.2.3	Macrophages.....	112
5.3.2.4	Neutrophils.....	113
5.3.2.5	Dendritic cells.....	113
5.3.2.6	Basophils and eosinophils.....	114
5.3.2.7	Natural killer cells	114
5.3.3	Adaptive immune system	114
5.3.3.1	Lymphocytes	115
5.3.3.2	Killer T cells.....	116
5.3.3.3	Helper T cells.....	116
5.3.3.4	B lymphocytes and antibodies.....	117
5.3.3.5	Immunological memory	117
5.3.3.6	Passive memory	117
5.3.3.7	Active memory and immunization.....	117
5.4	Immune diseases	117
5.4.1	Immunodeficiency.....	118
5.4.1.1	Primary immunodeficiency	118
5.4.1.2	Acquired immunodeficiency	118
5.5	Autoimmunity	118
5.5.1	Classifications of autoimmune diseases.....	119
5.6	Diagnosis of immune diseases	119
5.6.1	Autoantibody test	119
5.7	Treatments of immune diseases	120
5.7.1	Diabetes mellitus type 1	120
5.7.1.1	Causes.....	120
5.7.1.2	Pathophysiology.....	120
5.7.1.3	Diagnosis.....	121
5.7.1.4	Management.....	122
5.7.1.5	Pancreas transplantation	122
5.7.1.6	Islet cell transplantation.....	123
5.7.1.7	Issues with insulin injections.....	123
5.7.1.8	Research trends.....	123
5.7.2	Myasthenia gravis	124
5.7.2.1	Symptoms	125
5.7.2.2	Treatment	125
5.8	Summary	126
5.9	Knowledge builder	126
	Further reading	128

Chapter 6 Recombinant DNA technology and therapeutic proteins.....	131
6.1 Introduction.....	131
6.2 Recombinant DNA technology	131
6.2.1 Steps of constructing a recombinant DNA	131
6.2.1.1 Transformation.....	133
6.2.1.2 Nonbacterial transformation.....	133
6.2.1.3 Phage introduction	133
6.3 Applications of r-DNA technology	133
6.3.1 Therapeutic proteins	134
6.3.1.1 Recombinant human insulin	135
6.3.1.2 Recombinant human growth hormone	135
6.3.1.3 Recombinant blood clotting factor VIII.....	135
6.3.1.4 Recombinant hepatitis B vaccine.....	135
6.3.2 Current market for therapeutic proteins.....	135
6.4 Major r-DNA products.....	136
6.4.1 Recombinant insulin.....	136
6.4.2 Recombinant tissue plasminogen activator.....	137
6.4.3 Recombinant erythropoietin.....	138
6.4.3.1 Applications of erythropoietin	139
6.4.4 Recombinant monoclonal antibodies	139
6.4.5 Recombinant interferon	140
6.4.5.1 Interferon alpha.....	141
6.4.5.2 Interferon beta-1a	141
6.4.5.3 Interferon gamma	141
6.4.6 Recombinant antibiotics	142
6.5 Problems associated with recombinant DNA technology	142
6.5.1 Recombinant DNA organisms.....	142
6.5.2 Donor and recipient organisms.....	143
6.5.3 Health hazards and biosafety.....	143
6.6 Research trends in recombinant DNA technology	144
6.7 Summary	144
6.8 Knowledge builder	144
Further reading	148
Chapter 7 Stem cell technology	153
7.1 Introduction.....	153
7.2 Significance of stem cells	153
7.3 Classification of stem cells.....	156
7.3.1 Embryonic stem cells	156
7.3.1.1 Historical perspective of ES cells.....	157
7.3.1.2 Isolation and culture of ESCs.....	158
7.3.1.3 Identification of ESCs	159
7.3.1.4 Differentiation of ESCs.....	159
7.3.2 Adult stem cells.....	159
7.3.2.1 Localization of adult stem cells	161
7.3.2.2 Identification of adult stem cells	161
7.3.2.3 Differentiation of adult stem cells	161
7.3.2.4 Transdifferentiation capabilities of adult stem cells.....	161

7.3.3	Embryonic and adult stem cells: Similarities and differences.....	162
7.4	Induced pluripotent stem cells	162
7.4.1	Production of iPSCs.....	164
7.4.1.1	First generation.....	164
7.4.1.2	Second generation.....	164
7.4.1.3	Human iPSCs	164
7.4.2	Identification of iPSCs.....	165
7.4.3	Differentiation into ectoderm, mesoderm, and endoderm lineages.....	165
7.5	Applications of stem cells	165
7.5.1	Heart damage.....	166
7.5.2	Blood cell formation	166
7.5.3	Baldness	166
7.5.4	Amyotrophic lateral sclerosis	166
7.5.5	Orthopedics.....	167
7.5.6	Infertility.....	167
7.6	Stem cell transplantation	167
7.6.1	Hematopoietic stem cell transplantation	167
7.6.1.1	Autologous transplantation.....	167
7.6.1.2	Allogeneic transplantation	168
7.6.1.3	Posttransplantation problems associated with HSCT.....	168
7.6.2	ESC transplantation.....	168
7.7	Stem cell-based therapy: Global perspective.....	169
7.8	Application of stem cells in drug testing	169
7.8.1	Significance of testing using human cells.....	169
7.8.2	ESCs and drug testing	169
7.9	Stem cell banks.....	170
7.9.1	Cord blood bank	170
7.9.1.1	Banking umbilical cord tissue	170
7.9.1.2	Collection and preservation of umbilical cord stem cells.....	171
7.9.1.3	Therapeutics use of umbilical cord stem cells.....	171
7.10	Hurdles in ESC research.....	171
7.11	Summary	172
7.12	Scholar's achievements	172
7.13	Knowledge builder	173
	Further reading	176
Chapter 8	Cell and tissue engineering.....	181
8.1	Introduction.....	181
8.2	Animal cell culture.....	181
8.3	Organ culture	181
8.3.1	Organ culture technique	181
8.3.1.1	Plasma clot	182
8.3.1.2	Raft methods	183
8.3.1.3	Agar gel	183
8.3.1.4	Grid method	183
8.3.1.5	Cyclic exposure to medium and gas phase.....	184
8.3.2	Advantages of organ culture	184
8.4	Culture media	184

8.4.1	Natural media	185
8.4.2	Artificial media	185
8.4.2.1	Functions of serum in the culture medium	185
8.4.2.2	Advantages of serum-free media	186
8.4.2.3	Disadvantages of serum-free media	186
8.4.2.4	Chemically defined media	187
8.4.2.5	Protein-free media	187
8.5	Culture wares	187
8.5.1	Roux bottle.....	187
8.5.2	Roller bottle	187
8.5.3	Multi-tray unit.....	187
8.5.4	Synthetic hollow fiber cartridge	187
8.5.5	Opticell culture system.....	188
8.5.6	Plastic film	188
8.5.7	Heli cell vessels	188
8.6	Classifications of cell transplantation.....	188
8.6.1	Autologous cells.....	188
8.6.2	Allogeneic cells	189
8.6.3	Xenogeneic cells.....	189
8.6.4	Syngeneic or isogenic cells	189
8.7	Bioengineered cells.....	189
8.7.1	Construction of scaffold	189
8.7.2	Synthesis of bioengineered cells.....	190
8.7.2.1	Nanofiber self-assembly.....	190
8.7.2.2	Textile materials	190
8.7.2.3	Solvent casting and particulate leaching.....	190
8.7.2.4	Gas foaming.....	190
8.7.2.5	Emulsification/freeze drying.....	191
8.7.2.6	Thermally induced phase separation	191
8.8	Significance of cell and tissue engineering.....	191
8.8.1	Biomaterials in tissue engineering.....	192
8.8.2	Synthetic polymers	192
8.8.3	Synthetic peptides	192
8.8.4	Amine-rich oligopeptides.....	193
8.8.5	Natural polymers as biomaterials	193
8.8.6	Polymer matrices	193
8.8.7	Resorption of biomaterials	194
8.8.8	Inducing tissue regeneration	194
8.8.9	Growth factors.....	195
8.8.10	<i>In situ</i> tissue regeneration.....	195
8.8.11	Bone grafts.....	197
8.8.12	Artificial nerve grafts.....	198
8.8.12.1	Synthetic nonresorbable nerve grafts	198
8.8.12.2	Synthetic resorbable nerve grafts	199
8.8.12.3	Bio-artificial nerve grafts	199
8.8.13	Hemoglobin-based blood substitutes	199
8.8.14	Bio-hybrid organs	199
8.9	Bioreactor	200
8.9.1	Types of bioreactor	200

8.9.1.1	Batch fermentation process	200
8.9.1.2	Continuous fermentation process	201
8.9.1.3	Aerobic fermentation.....	201
8.9.1.4	Anaerobic fermentation	201
8.9.2	Bioreactor design	201
8.10	Cell banking	202
8.11	Trends in tissue engineering.....	202
8.12	Challenges of tissue engineering	202
8.12.1	Nonavailability of reliable source of cells.....	203
8.12.2	Adequate quantities of cells and tissues with desired properties	203
8.12.3	Tissue engineering and reperfusion injury	203
8.13	Summary	204
8.14	Scholar's achievements	204
8.15	Knowledge builder	204
	Further reading	206
Chapter 9	Molecular diagnostics and forensic science	211
9.1	Introduction.....	211
9.2	History of diagnostic tests.....	211
9.3	Diagnostic process.....	212
9.4	Classification of diagnostic tests.....	213
9.4.1	Invasive test	213
9.4.2	Minimally invasive procedure	213
9.4.2.1	Minimal incision technique	214
9.4.3	Noninvasive test	214
9.5	Characteristics of diagnostic tests.....	214
9.6	Molecular diagnostic.....	214
9.6.1	Fluorescence <i>in situ</i> hybridization.....	215
9.6.2	Preparation, hybridization process, and types of FISH techniques.....	216
9.6.2.1	Single molecule RNA FISH	217
9.6.2.2	Q-FISH.....	217
9.6.3	Medical applications of FISH.....	218
9.6.3.1	Species identification	218
9.6.3.2	Lab-on-a-chip	219
9.7	Diagnostic application of polymerase chain reaction	219
9.7.1	Application of PCR technology	219
9.7.1.1	Infectious disease.....	220
9.7.1.2	Blood screening.....	220
9.7.1.3	Genetic testing.....	221
9.8	Forensic science.....	221
9.8.1	Classification of forensic science	221
9.8.1.1	Forensic anthropology	221
9.8.1.2	Forensic archaeology	222
9.8.1.3	Forensic fingerprinting	222
9.8.1.4	DNA profiling	222
9.8.1.5	Forensic dentistry	222
9.8.1.6	Forensic pathology.....	222

9.8.1.7	Forensic serology	223
9.8.1.8	Forensic toxicology	223
9.8.2	Forensic psychology	224
9.8.2.1	Career opportunities in forensic psychology	224
9.8.3	Forensic accounting.....	225
9.9	Genetic fingerprinting	226
9.9.1	Restriction fragment length polymorphism analysis	226
9.9.1.1	Short tandem repeat analysis.....	226
9.9.1.2	DNA family relationship analysis.....	227
9.9.1.3	Y chromosome analysis	228
9.9.1.4	Mitochondrial DNA analysis.....	228
9.10	Summary	228
9.11	Scholar's achievements	229
9.12	Knowledge builder	229
	Further reading	231
Chapter 10 Genetic disorders and gene therapy		237
10.1	Introduction.....	237
10.2	Genetic epidemiology	237
10.3	Epigenetics	237
10.3.1	Mechanism of epigenetics	238
10.3.1.1	DNA methylation.....	238
10.3.1.2	RNA transcripts and their encoded proteins	240
10.3.1.3	MicroRNAs	240
10.3.1.4	Small RNA	241
10.3.1.5	Prions.....	241
10.4	Genetic disorders: Classification	241
10.4.1	Single gene inheritance.....	242
10.4.2	Multifactorial inheritance.....	242
10.4.3	Chromosome abnormalities.....	242
10.4.4	Mitochondrial inheritance	243
10.5	Causes of genetic diseases.....	244
10.6	Gene therapy and types.....	245
10.6.1	Somatic gene therapy	245
10.6.1.1	<i>Ex vivo</i> somatic gene therapy	246
10.6.1.2	<i>In vivo</i> somatic gene therapy	246
10.7	Importance of vectors in gene therapy	248
10.7.1	Retroviruses	248
10.7.2	Adenoviruses	249
10.7.3	Adeno-associated viruses.....	249
10.7.4	Envelope protein viruses.....	251
10.7.5	Replication competent viruses.....	251
10.7.6	Nonviral-mediated gene therapy	251
10.7.6.1	Electroporation.....	252
10.7.6.2	Gene gun.....	252
10.7.6.3	Sonoporation.....	252
10.7.6.4	Magnetofection.....	253
10.7.6.5	Synthetic oligonucleotides.....	253

10.7.6.6	Lipoplexes and polyplexes	253
10.7.6.7	Dendrimer.....	253
10.7.6.8	Hybrid methods.....	254
10.7.6.9	Challenges of nonviral-mediated gene therapy	254
10.8	Applications of gene therapy	254
10.9	Gene therapy clinical trials: The US scenario.....	256
10.9.1	Accomplished clinical trials.....	256
10.9.1.1	Gene therapy for ADA–SCID.....	256
10.9.1.2	Liver transplantation with ADV-TK gene therapy.....	256
10.9.1.3	Gene therapy for chronic granulomatous diseases	256
10.9.1.4	Gene therapy for Alzheimer’s disease: Clinical trial.....	256
10.9.1.5	Gene therapy in patients with severe angina pectoris	257
10.9.2	Terminated clinical trials.....	257
10.10	Ethical issues in gene therapy.....	257
10.10.1	Ethical issue with gene therapy.....	257
10.11	Technical and regulatory issues with gene therapy.....	258
10.11.1	Short-lived nature of gene therapy	258
10.11.2	Immune response.....	258
10.11.3	Problems with viral vectors	258
10.11.4	Multigene disorders	258
10.12	Summary	258
10.13	Scholar’s achievements	259
10.14	Knowledge builder	259
	Further reading	261
Chapter 11	Synthetic biology and nanomedicine	263
11.1	Introduction.....	263
11.2	Significance of synthetic biology	263
11.3	Applications of synthetic biology.....	265
11.3.1	Genome design and construction	265
11.3.2	Synthetic genome.....	265
11.3.3	Applied protein design.....	266
11.3.4	Natural product synthesis.....	267
11.3.5	Creation of standardized biological parts and circuits.....	267
11.4	Challenges in synthetic biology	268
11.4.1	Unpredictable circuit.....	269
11.4.2	Complexity of circuit.....	269
11.5	Health risk and ethical issues associated with synthetic biology	269
11.5.1	Risk of testing in the open environment.....	270
11.5.2	Risk of deliberate misuse.....	270
11.5.3	Online selling of oligonucleotides	270
11.6	Nanomedicine	271
11.7	Nanomaterial.....	271
11.7.1	Classification of nanomaterials.....	271
11.7.1.1	Fullerenes	271
11.7.1.2	Nanoparticles	272
11.7.1.3	Solution–Gel	272

11.8	Application of nanomaterials in medicine.....	273
11.8.1	Therapeutic delivery	273
11.8.2	Biopharmaceutical drug delivery.....	274
11.8.2.1	Cancer.....	274
11.8.2.2	Visualization.....	275
11.8.2.3	Nanoparticle targeting.....	275
11.8.3	Neuro nanodevice	276
11.8.4	Nanorobots	276
11.8.5	Nanocell repair	276
11.8.6	Nanonephrology.....	277
11.9	Safety issues associated with nanomaterials.....	277
11.9.1	Solutions for safety issues associated with nanomaterials.....	278
11.10	Ethical issues related to nanomaterials	278
11.11	Summary	279
11.12	Scholar's achievements	279
11.13	Knowledge builder	279
	Further reading	281
Chapter 12	Pharmacogenomics and predictive medicine	283
12.1	Introduction.....	283
12.2	Drug development.....	283
12.2.1	Drug discovery	283
12.2.1.1	Drug targets.....	284
12.2.1.2	Drug screening.....	285
12.2.1.3	Preclinical testing of drug candidate.....	286
12.2.1.4	Clinical testing of drug candidate.....	286
12.2.1.5	Challenges of current drug discovery	288
12.3	Pharmacogenomics and drug discovery process	289
12.3.1	Better and safer drugs.....	290
12.3.2	Determining accurate drug dosages.....	290
12.3.3	Advanced screening for diseases.....	290
12.3.4	Improved vaccines development.....	291
12.3.5	Decrease in the overall cost of health care.....	291
12.4	Current application of pharmacogenomics	291
12.5	Challenges of pharmacogenomics	292
12.5.1	Gene variations and drug response.....	292
12.5.2	Limited drug options	293
12.5.3	Disincentives for drug companies	293
12.5.4	Educating health care providers.....	293
12.6	Predictive medicine.....	293
12.6.1	Benefits of predictive medicine	293
12.6.1.1	Newborn screening	294
12.6.1.2	Diagnostic testing	294
12.6.1.3	Medical bioinformatics	294
12.6.1.4	Prenatal testing	294
12.6.1.5	Genetic disease carrier testing.....	295
12.6.2	Limitations of predictive medicine	295
12.6.3	Ethical issues associated with predictive medicine	295

12.7 Summary	296
12.8 Knowledge builder	296
Further reading	298
Chapter 13 Bioethics.....	301
13.1 Introduction.....	301
13.2 Bioethics in historical perspective.....	301
13.3 Human cloning	302
13.3.1 Government response.....	303
13.3.1.1 United Nations	303
13.3.1.2 Australia.....	303
13.3.1.3 European Union.....	303
13.3.1.4 United States of America	303
13.3.1.5 United Kingdom	304
13.3.2 Religious views	304
13.4 Organ transplantation.....	304
13.4.1 Sociopolitical reasons.....	305
13.4.2 Religious understanding	305
13.5 Embryo screening.....	305
13.6 Xenotransplantation.....	306
13.7 Human embryonic stem cells	306
13.8 Gene therapy	307
13.9 Vaccines.....	308
13.10 DNA fingerprinting.....	308
13.11 Biometrics	309
13.12 Nanomedicine	309
13.13 Summary	309
13.14 Scholar's achievement	309
13.15 Knowledge builder	310
Further reading	311
Chapter 14 Biobusiness and intellectual property rights	315
14.1 Introduction.....	315
14.2 What is business?.....	315
14.2.1 Business plan.....	315
14.2.2 Executive report.....	316
14.2.3 Competitor analysis	316
14.2.4 Market analysis.....	316
14.2.5 Financial plan.....	317
14.3 Business of biotechnology.....	317
14.4 Benefits of biotechnology	317
14.4.1 Heal the world.....	318
14.4.2 Fuel the world	319
14.4.3 Feed the world.....	319
14.5 Investment in biotechnology business?.....	319
14.5.1 Benefits of investing in biotechnology business	319
14.5.1.1 Job satisfaction.....	320
14.5.1.2 Fastest-growing job sector.....	320
14.5.1.3 Available funding	320

14.6	Financial stocks and biotechnology business	320
14.7	Regulatory and compliance issues in biobusiness	320
14.7.1	World Health Organization	321
14.7.2	U.S. Food and Drug Administration	322
14.7.2.1	Drug regulations	322
14.7.2.2	Biotechnology product regulations	323
14.7.3	International Conference on Harmonization	323
14.8	Intellectual property rights in health care business.....	323
14.8.1	Patents	323
14.8.1.1	Intellectual property protection in biotechnology.....	324
14.8.1.2	Rights in plant varieties	325
14.8.1.3	International treaties	325
14.9	Patenting and partnership in biotechnology industries.....	326
14.10	Biotechnology capital market in the United States.....	326
14.11	Mergers and acquisitions of biotechnology companies.....	327
14.11.1	Merger trends in India.....	328
14.12	Summary	329
14.13	Knowledge builder	329
	Further reading	330
Chapter 15	Career opportunities	333
15.1	Introduction.....	333
15.2	Research and development jobs	333
15.2.1	Basic research labs	334
15.2.2	Preclinical labs	334
15.2.3	Formulation labs	335
15.2.4	Clinical research	336
15.2.5	Production and manufacturing.....	336
15.2.6	Quality assurance.....	336
15.2.6.1	Improve quality.....	337
15.2.6.2	Low cost	337
15.2.6.3	Reputation.....	337
15.2.6.4	Reduce execution time	337
15.2.6.5	Compliance to standards	337
15.2.6.6	Difference between quality control and quality assurance.....	337
15.2.6.7	Jobs opportunities.....	338
15.2.7	Patent and intellectual property rights	339
15.2.7.1	Job opportunities in IP law.....	339
15.2.8	Financial management.....	340
15.2.8.1	Biotechnology management course of study.....	340
15.2.8.2	Biotechnology management career opportunities.....	341
15.2.8.3	Postgraduate diploma and postgraduate courses	341
15.2.8.4	Biotechnology management career prospects.....	341
15.2.8.5	Biotechnology management program	342
15.2.8.6	Self-employment biotechnology	342
15.3	Top biotechnology companies: Global scenario.....	342
15.4	Emerging technologies of biotechnology.....	342
15.5	Online biotechnology career information	342

15.6 Professional associations for networking	347
15.7 Summary	347
Further reading.....	347
Glossary.....	349

Preface

Over the past few decades, we have seen an exponential growth in biotechnology products especially in the medical and health care sectors. Most prominently the discovery of penicillin (an antibiotic), recombinant insulin, and cell-based therapy have completely revolutionized the field of medical diagnosis and treatments. Biotechnology is a field of applied biology that involves the use of living organisms with engineering tools to develop useful therapeutic products. Biotechnology has applications in four major industrial areas: health care (medical), crop production and agriculture, nonfood (industrial) uses of crops and other products (e.g., biodegradable plastics, vegetable oil, biofuels), and environmental uses. Among these, the medical aspects of biotechnology have been extensively used in the development of health products and diagnostic tools. In medicine, modern biotechnology finds promising applications in such areas as drug production, pharmacogenomics, gene therapy, and genetic testing. The field of medical biotechnology keeps growing with new discoveries and products. It becomes necessary to have a book that addresses the basic to the advanced level and from laboratory to clinic levels of medical biotechnology in a lucid and concise way.

There are many books available in the market that discuss the applications and fundamentals of biotechnology, but there is no single book available that deals with all aspects of medical biotechnology. Many times, students and researchers need to refer to various books to get a holistic view of the recent progress in medical biotechnology. In this book, I collate and discuss topics that are associated with medicine. The book consists of 15 chapters. Each chapter begins with a brief introduction of the topic followed by significances and applications, including colorful illustrations to explain the significance of particular topics. I have also included the names and brief contributions of important scientists and a chapter-focused bibliography at the end of each chapter to help the reader to learn each topic with great ease and interest. Chapter 1 deals with an introduction to biotechnology in medical sciences. Chapter 2 discusses human diseases and epidemiology. Chapter 3 focusses on bacteriology and antibiotics. Chapter 4 furnishes details with regard to virology and vaccines. Chapter 5 deals with immunology and monoclonal antibodies. Chapter 6 provides details on recombinant DNA technology and therapeutic proteins. Chapter 7 discusses stem cell technology. Chapter 8 covers tissue engineering. Chapter 9 includes molecular diagnostics and forensic science. Chapter 10 contributes to gene therapy. Chapter 11 focusses on synthetic biology and nanomedicine. Chapter 12 contributes to pharmacogenomics. Chapter 13 discusses bioethics. Chapter 14 deals with biobusiness and intellectual property rights. And Chapter 15 discusses career opportunities.

Acknowledgments

First and foremost, I am grateful to Almighty Allah who gave me the strength to write a second book on topics in biotechnology. I am thankful to CRC Press and especially to Dr. Michael J. Slaughter, executive editor, for having complete faith in me and giving yet another opportunity to write this book. My first book titled *Biotechnology Fundamentals* was published in 2011 and has been adopted as a textbook in the United States, Canada, and Finland. I am thankful to many people who helped me in producing this book, especially to Stephanie Morkert, project coordinator, and Ed Curtis, project editor, Taylor & Francis Group, for their valuable help in completing the book in record time. I am also thankful to Syed Mohamad Shajahan for copyediting and to the entire team of CRC Press/Taylor & Francis Group for making this book a reality.

I would like to thank the entire management team, faculty, and staff of Manipal University, India and Dubai, for their constant support. I am thankful to all my teachers and mentors, especially to Professor Nishikant Subhedar and the late Professor Obaid Siddiqi, FRS, for their training.

I am thankful to all my friends, well-wishers, and colleagues for their support and cooperation. I am grateful to all my family members, especially my father, the late Nayeemuddin Khan, and mother, Sarwari Begum; my brothers Aftab Alam Khan, Javed Alam Khan, Intekhab Alam Khan, and Dr. Sarfaraz Alam Khan; my sisters Sayeeda Khanum, Kausar Khanum, Kahkashan Khanum, and Aysha Khanum; my wife Samina Khan; my sons Zuhayr Ahmad Khan, Zaid Ahmad Khan, and Zahid Ahmad Khan; and my daughter Azraa Khan; father-in-law Abdul Qayyum Siddiqui; and mother-in-law Uzma Siddiqui for their constant support and prayers.

I welcome your comments and suggestions to make this book error-free and more thought-provoking in the future. You may send your comments to the address below. Enjoy reading!

Firdos Alam Khan, PhD

Professor and Chairperson

School of Life Sciences

Manipal University Dubai Campus

P.O. Box 345050 Dubai

United Arab Emirates

Email: firdoskhan1969@gmail.com

Author

Firdos Alam Khan is a professor and chairperson in the School of Life Sciences, Manipal University Dubai Campus, Dubai, United Arab Emirates. He earned his doctorate from Nagpur University, India in 1997. He has more than 20 years of research and teaching experience.

Dr. Khan did his first postdoctoral research from the National Centre for Biological Sciences in Bangalore, India, where he worked on a World Health Organization sponsored research project titled Olfactory Learning in *Drosophila melanogaster*. In 1998, Dr. Khan moved to the United States and joined the Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, and worked on the research project titled Axonal Nerve Regeneration in Adult Syrian Hamster. In 2001, he returned to India and joined Reliance Life Sciences, a Mumbai-based biotechnology company, where he was associated with adult and embryonic stem cell research projects. Dr. Khan showed that both adult and embryonic stem cells have the ability to differentiate into neuronal cells. He also developed novel protocols to derive neuronal cells from both adult and embryonic stem cells.

Over the past 7 years, Dr. Khan has been associated with the Department of Biotechnology, Manipal University Dubai as chairperson. He teaches bioethics and biotechnology business courses to graduate and postgraduate students.

Dr. Khan's area of specialty in biotechnology includes stem cell technology, pharmacology, and neuroscience. He has written numerous articles in various national and international journals in the areas of neuroscience, neuropharmacology, and stem cell biology. He holds two US patents in the field of stem cell technology. He has been associated with various international scientific organizations such as the International Brain Research Organization, France, and Society for Neuroscience, USA. He has presented his research work at more than 23 different national and international conferences in India, Singapore, UAE, and the United States.

chapter one

Introduction to biotechnology in medical sciences

1.1 Introduction

The term medical biotechnology is the application of living organisms or cells or tissues to produce pharmaceutical and diagnostic products that help to treat and to prevent the progress of human diseases. One of the best-known examples of medical biotechnology is the production of antibiotics for treating various bacterial infections; these antibiotics are produced by using known microorganisms. Similarly, over the past few decades various other types of products have been produced, which include biopesticides, pest-resistant crops, and bioremediation techniques and many more. The most remarkable discovery made in recent times is the production of human proteins (insulin) outside of the human body, which has completely revolutionized the medical treatment modality. The synthesis of human insulin and growth hormones are considered to be the rewards of modern biotechnology. In both insulin and growth hormone production, scientists have used recombinant DNA technology to be administered in patients suffering from various incurable diseases such as diabetes and genetic disorders. It has been suggested that one of the major problems in treating patients with cancer and diabetes conditions is not being able to completely eradicate the disease. The only available option for any physician is to either go for drug therapy or surgical interventions to give symptomatic relief.

1.2 What is biotechnology all about?

The field of biotechnology has been in use for ages in various forms, which include the growing of better crops (agricultural biotechnology) and animal breeding (animal biotechnology). Similarly, the use of biotechnology has been around for thousands of years, especially the application of microorganisms in the production of cheese and yogurt (food biotechnology). In addition, the tools of biotechnology have been implied in animal husbandry, to develop pest-resistant crops, bioremediation (environmental biotechnology), as well as in bioethanol production. But the most promising application of biotechnology is found to be in the medical field by generations of biotherapeutics (insulin, growth hormones) and diagnostics tools (PCR, FISH, micro-array technique). Before we discuss various applications of medical biotechnology, let us briefly go through the historical aspects of biotechnology and this information will make you to understand the field better. It all began with the discovery made by Sir Alexander Fleming in the year 1918 where he observed that the mold *Penicillium* inhibited the growth of human skin disease-causing bacteria called *Staphylococcus aureus*. The discovery by Sir Alexander Fleming led to the making of antibiotics that we use today. These antibiotics are highly recommended and extensively used medicinally for bacterial infections (Figures 1.1 and 1.2). These antibiotics are basically substances produced by microorganisms that normally inhibit the growth of




Figure 1.1 Application of microorganisms and viruses in making of medicine using bioreactor and recombinant DNA technology.




Figure 1.2 The pioneering experiment conducted by Dr. Alexander Fleming resulted in the discovery of the penicillin drug, an antibiotic drug.

other microorganisms. Later on, antibiotics became widely available as a drug for treating microbial infections in human beings, especially with the development of penicillin (Figure 1.3) as the most used antibiotic. Currently, a variety of microorganisms have been used to generate thousand liters of antibiotic drugs by using advanced biotechnology tools.

The field of biotechnology has taken a leap with the discovery of the double-helix structure of the deoxyribose nucleic acid (DNA) molecule and the credit goes to one research publication titled "This structure has novel features which are of considerable biological interest" authored by James Watson and Francis Crick in 1953, which claimed to discover the structure of the human DNA helix, the molecule that carries genetic information from one generation to the other. Nine years later, in the year 1962, they shared the Nobel Prize with Wilkins for cracking one of the most important of all biological puzzles. This discovery has led to the birth of genetic mapping, manipulation, and genetic engineering-type fields. Surprisingly, with the help of genetic engineering, the gene of interest can be cut and inserted into the genome of other living organisms (microorganisms and viruses) and




Figure 1.3 Structures of penicillin G, penicillin V, and ampicillin.

this process of gene insertion and manipulation is called recombinant DNA technology. Over the past few years recombinant DNA technology has been extensively employed to generate therapeutic products (insulin and growth hormones) for treating human diseases. With a rapid increase in the number of patient's worldwide, there has been a tremendous scope to identify and create medicine for various human diseases. Thankfully with the availability of biotechnology tools, now it is possible to develop therapy for various diseases. In Table 1.1, major biotechnology-related discoveries and milestones are listed to appreciate the contribution of biotechnology in human health care.

1.3 Medical products developed by using biotechnology tools

One of the salient features of medical biotechnology is the contribution of arrays of products, which include treatment of bacterial infections, diabetes, immune disorders, cancer, and degenerative conditions such as heart infarction and neurodegenerative diseases (i.e., Parkinson's disease, Alzheimer's disease, or stroke diseases). We have briefly discussed below some of the major biotechnology-based products which have been widely used around the world.

1.3.1 Antibiotics

Penicillin is one of the earliest discovered antibiotics which is basically derived from molds such as *Penicillium*. Penicillin was discovered by Scottish scientist and Nobel laureate Sir Alexander Fleming in 1928. It all started with a basic experiment where Sir Fleming noticed a Petri dish containing *Staphylococcus* plate culture which he had mistakenly left open was contaminated by blue-green mold, which had formed a visible growth. But surprisingly he also found that there was a circle of inhibited bacterial growth around the mold. Later on, Sir Fleming hypothesized that the mold was releasing a substance that was preventing the growth and could contain a substance with antibiotic properties. In order to prove his hypothesis, he grew a pure culture and discovered the first antibiotic substance from the *Penicillium* mold, known as *Penicillium notatum*. Sir Alexander showed that *P. notatum* when grown in the appropriate substrate caused the release of chemical substances and these chemical substances were named as antibiotics. He later on named

Table 1.1 Milestones in Medical Biotechnology

Year	Nature of discovery/milestone
1882	Chromosomes discovered in salamander larva
1944	DNA is a hereditary material
1963	Genetic materials decoded
1971	The world's first biotech company is founded in California, US
1979	First biotech product human growth hormone, which is also becoming the first recombinant biotech drug manufactured and marketed by a biotechnology company
1980	Genentech becomes the first biotech company to go public, generating \$35 million in its initial public offering
1983	Stanford School of Medicine becomes the first to screen blood to prevent AIDS transmission
1984	World's first DNA fingerprinting technique is developed
1984	Chiron Corporation announced the first cloning and sequencing of the entire HIV virus genome
1984	Genentech obtains USFDA approval to market human growth hormone, the first recombinant product to be sold by a biotechnology company
1986	The USFDA awards Chiron Corporation, a license for the production of first recombinant vaccine to battle the hepatitis B virus
1988	The "Harvard Mouse" becomes the first mammal patented in the United States
1991	Cancer patients are treated with a gene therapy that produces the tumor necrosis factor, a natural tumor-fighting protein
1995	The first full gene sequence of a living organism other than a virus is completed for the bacterium hemophilic influenza
1997	A sheep named "Dolly" becomes the first mammal cloned
2002	First vaccine against cervical cancer development

that chemical substance as penicillin. Soon after this discovery, penicillin was considered to be the most effective drug against bacteria (Gram-positive bacteria), and not at all effective against Gram-negative bacteria. The discovery of penicillin marks the beginning of the antibiotic production and so far more than 200 different types of antibiotics have been produced (Figure 1.3).

1.3.2 Recombinant insulin

Another discovery which was made in the medical field was the recombinant DNA technology, which has completely revolutionized disease treatments especially in the Type 1 diabetes mellitus, where insulin-producing cells become dysfunctional and do not produce sufficient amount of insulin to regulate blood-sugar level. In a healthy human being, insulin regulates glucose metabolism in the body. In diabetic conditions, the level of insulin decreases which causes the elevation of the blood sugar level and this clinical condition is known as diabetes mellitus. One of the best treatments of diabetes mellitus is insulin injections, where insulin is injected into the patient's body and the insulin regulates the blood-sugar level. The insulin is either synthesized chemically or produced by recombinant DNA technology. These synthesized insulins are used medically to treat patients with Type 1 diabetes mellitus, whereas patients with Type 2 diabetes mellitus are insulin resistant.




Figure 1.4 Making of human insulin by recombinant DNA technology.

However, some patients with Type 2 diabetes may eventually require insulin treatment if other medications fail to control blood glucose levels adequately, though this is somewhat uncommon. With the advent of recombinant DNA technology, it became possible to make insulin outside the human body and this biosynthetic insulin is now manufactured for widespread clinical use. More recently, scientists have succeeded in introducing human insulin gene into plants in order to produce human insulin in plants, and the safflower plant has been used for this purpose. In addition to recombinant DNA technology, there are other ways to synthesize human insulin outside the human body and they are usually referred to as insulin analogues and these analogues are chemically synthesized (Figure 1.4). One of the major hurdles in the diabetes treatment is the delivery of insulin, as insulin cannot be taken orally because it will not be absorbed properly and will lose its biological activity. In recent years, an attempt has been made to develop insulin which can be safely given through the oral route or sublingually. It has been reported that insulin can be taken as subcutaneous injections; few companies have also attempted to develop an oral form of insulin and trials are underway.

1.3.3 Vaccines

The vaccine is basically a biological preparation that improves the human immune defense system to fight diseases. The vaccines normally contain an agent that diligently resembles a disease-causing bacteria, and is frequently produced from debilitating or killed forms of the microorganisms. Upon injection into the human body, the vaccine can stimulate the body's immune system to recognize the agent as a foreign body, and recognize it, so that the immune system can recall and destroy or kill any of these microorganisms that later




Figure 1.5 Making of vaccine.

infect the human body. In a simpler way, the vaccine basically trains the human body to defend or fight or kill the microorganisms. The vaccines are classified based on its application; the vaccines that are used to prevent the effects of an upcoming infection by any natural or wild pathogen are called prophylactic, and the vaccines which are used against cancer are called therapeutic vaccines (Figure 1.5).

The story of vaccine development dates back to the seventeenth century when Edward Jenner found a milkmaid infected with smallpox, and a few days later he took pus from the hand of the milkmaid with cowpox and inoculated an eight-year-old boy with it. After six weeks he found that the boy did not contract smallpox. After a few years, Sir Louis Pasteur adapted Jenner's idea of developing a rabies vaccine and, subsequently, vaccine development progress started and became a matter of national concern. After that obligatory vaccination laws were passed in various countries around the globe. During the twentieth century, we have seen an introduction of several successful vaccines against diseases such as diphtheria, measles, mumps, and rubella. Interestingly, the major achievement was done in the 1950s when the polio vaccine was made and clinically used; also vaccines were synthesized to eradicate smallpox.

1.3.4 Monoclonal antibodies

Another milestone achieved in the beginning of the twentieth century was the making of monoclonal antibodies, which was proposed by Paul Ehrlich. He suggested that drug compounds can be accurately, precisely, and specifically delivered along with monoclonal antibodies. Monoclonal antibodies are mono-specific antibodies as they are made by identical cells that are all clones of a distinctive parent cell (Figure 1.6). Currently, it is possible to produce monoclonal antibodies that specifically bind to that antigen and have a variety




Figure 1.6 Making of monoclonal antibodies.

of applications, especially to detect or purify that substance (antigen), and has become an important tool in diagnostics and biomedical research.

In diagnostics and biomedical research, monoclonal antibodies are very useful tools. First, they are extremely specific; that is, each antibody binds to the specific site of the antigen. Second, some antibodies, once activated by the occurrence of a disease, continue to confer resistance against that disease; classic examples are the antibodies to the childhood diseases chickenpox and measles. Another important application of monoclonal antibodies is to develop vaccines against various diseases. As you are aware, a vaccine is made from bacteria or viruses either killed or inactivated. Upon introduction into the human body this vaccine stimulates the production of antibodies against the antigens to fight back the diseases. The production of monoclonal antibodies involves human and mouse hybrid cells and this technology is known as hybridoma technology. During monoclonal antibody production, tumor cells are merged with mammalian cells that produce an antibody against a particular antigen. The result of these merged tumors with mammalian cells is called hybridoma, which can frequently produce antibodies. These antibodies are called monoclonal antibodies because they come from only one type of cell; whereas, the antibodies that are produced by conventional methods contain many kinds of cells and are called polyclonal antibodies.

1.3.5 Bioengineered tissues

Over the last decade, tissue engineering became the most fascinating medical field, especially in body-parts reconstruction or cosmetic surgery areas. The basic concept about tissue engineering is to make human tissues through *in vitro* methods under controlled laboratory conditions and the making of such tissues is called bioengineered tissues. The

Table 1.2 Research in Tissue Engineering

Bioengineered cells/tissues	Properties
Biomaterials	These include novel biomaterials that are designed to direct the organization, growth, and differentiation of cells in the process of forming functional tissue by providing both physical and chemical cues
Biomolecules	These include angiogenic factors, growth factors, differentiation factors, and bone morphogenic proteins
Engineering design aspects	These include two-dimension cell expansion, three-dimension tissue growth, bioreactors, vascularization, cell and tissue storage and shipping
Biomechanical aspects of design	These include properties of native tissues, identification of minimum properties required of engineered tissues, mechanical signals regulating engineered tissues, and efficacy and safety of engineered tissues
Informatics to support tissue engineering	These include gene and protein sequencing, gene-expression analysis, protein expression and interaction analysis, quantitative cellular image analysis, quantitative tissue analysis, in silicon tissue and cell modeling, digital tissue manufacturing, automated quality assurance systems, data mining tools, and clinical informatics interfaces

definition of tissue engineering covers a broad range of applications in the healthcare field, however, in practice the term tissue engineering closely relates to repair or replacing portions of, or whole, human body tissues which include neurons, cardiomyocytes, bone, and cartilage. The bioengineered tissues are constructed by integrating certain mechanical and structural properties for proper functioning in the human body, so one can say that bioengineering is basically the use of a combination of cells, engineering, and bio-compatible materials, and is finally suitable to improve or replace biological functions (Table 1.2). The bioengineered field was once categorized as a sub-field of biomaterials, but having grown in scope and application it is considered as a field in its own right (Figure 1.7). Tissue engineering is an emerging multidisciplinary field involving biology, medicine, and engineering that is likely to revolutionize the ways we improve the health of millions of people worldwide by repairing, maintaining, or enhancing tissue and organ function. The tissue engineering can also have diagnostic applications where the human cells or tissues are used to test drug metabolism and drug uptake, toxicity, and pathogenicity.

1.3.6 *Adult stem cell therapy*

Over the last few years, there has been tremendous interest in adult stem cells for the autologous cell transplantation as these specialized cells have the potential ability to repair or restore the dysfunctional cells or tissues in the human body afflicted with various diseases that include blood cancer and neurological disorders. The stem cells are generally found in all multicellular organisms and they are characterized by the ability to renew themselves through cell division and differentiate into a varied range of specialized cell types. Moreover, mammalian stem cells may be broadly classified into two major types: adult stem cells and embryonic stem cells (ESCs) that are isolated from the inner cell mass of blastocysts.

One of the main roles of adult stem cells is that they remain in an undifferentiated state in the human body and multiply by cell division to replenish dying cells and restore damaged tissues and organs. The adult stem cells are also known as somatic stem cells;




Figure 1.7 Tissue engineering.

these stem cells can be found in both juvenile and adult ages. Moreover, adult stem cells are specialized cells that have the capability to divide and generate all cell types of the organ from which they originate, and can also possibly regenerate the entire organ. Unlike ESCs, the use of adult stem cells is not contentious as they are derived from adult source or tissue rather than by killing human embryos. Moreover, adult stem cells have been in use for many years predominantly in the treatment of cancer (such as leukemia and related bone and blood cancers) employing bone marrow transplants. Interestingly, the majority of the government funding especially in the United States is confined to adult stem cell-based research. Among adult stem cells, hematopoietic stem cells (HSCs) and mesenchymal stem cells (MSCs) are found to be the most successful stem cells because they can be clinically used in patients. These stem cells can be directly injected or placed at the site of repair or injected through vascular delivery (Figure 1.8).

1.4 Emerging trends

In addition to above-mentioned fields, there are other fields which are emerging and are in the initial phase of development. These emerging fields will provide improved technology or tools to treat or diagnose various diseases.

1.4.1 Embryonic stem cells

Over the last few years ESCs have been a highly discussed and debated scientific topic at all levels which include public life, scientific forums, ethical, legal, and political platforms. Before we discuss the ethical or legal issues associated with ESCs, we will first learn what ESCs are all about. The ESCs are basically pluripotent stem cells isolated from the inner cell mass of the blastocyst, which is an early-stage embryo. Moreover, human embryos reach the blastocyst stage 4 to 5 days post fertilization, at which time they consist of about




Figure 1.8 Adult stem cells.

50–150 cells. In addition to this, ESCs are adept at propagating themselves for an indefinite period under controlled culture situations. The culture and propagation of ESCs through in vitro methods is considered to be the best technology to culture human cells in large quantities and to be engaged as valuable tools for both research and cell-based therapy (Figure 1.9).




Figure 1.9 Embryonic stem cells.

One of the best applications of ESCs is to provide a large supply of required cells to be used as cell-based therapy and tissue replacement in patients who are suffering from degenerative diseases. Moreover, a number of diseases that could possibly be treated by ESCs are cancers, diabetes, Parkinson's disease, Alzheimer's disease, stroke, blindness, and spinal cord injuries. In contrast to its various therapeutic applications, the issues related to ESCs need to be resolved before making them useful for human use. These issues are the problem of immune rejection associated with allogeneic stem cell transplantation. These problems can be solved by using adult stem cells in autologous transplantation. Besides, cell-based therapy, the ESCs can be used as diagnostic tools to study an early human development and genetic disease, as well as in vitro drug testing. Other issues related to ESCs transplantation is that there is a possibility that transplanted stem cells could form tumors and have the possibility of becoming cancerous if cell division continues uncontrollably. Contrary to this, supporters of ESCs research argue that such research should be continued because the resultant research findings will have significant medical potential. The recent development of induced pluripotent stems cells (iPSc) has created tremendous interest among scientists, as adult stem cells can be converted into pluripotent stem cells and there is no need to kill the human embryos.

In spite of all controversies over ethical use of human ESCs, on January 23, 2009, Geron Corporation, USA, has received an approval from US Food and Drug Administration (FDA) to test ESCs in humans. The Phase 1 clinical trial for transplantation of a human-ES-derived cell population into spinal cord-injured individuals became the first human ES cell human trial. The Phase 1 clinical study was conducted on eight to ten paraplegic patients who have had their injuries no longer than two weeks before the trial began, and stem cells were injected before the formation of scar in the tissue. Nevertheless, the researchers are stressing that the injections are not expected to fully cure the patients and restore all mobility. The success of such clinical trials goes back to the experiments conducted by University of California, USA, and which was supported by Geron Corporation of Menlo Park (Biotechnology Company), California. The results of an animal study showed that there was functional improvement in locomotive recovery in spinal cord-injured rats after stem cell transplantation. Interestingly, the first trial is mainly for testing the safety of cell-based transplantation. However, the trial had been put on hold in August 2009 due to apprehensions made by the FDA regarding a small number of microscopic tumors found in several treated rat models, but the hold has been lifted since.

1.4.2 Human genome project

The Human Genome Project (HGP) was an international collaborative research project with a primary aim to decode the human DNA genome. The main objective of the HGP was to map about 20–25 k genes of the human genome from both a physical and functional perspective. The initial task of the project was to identify the full set of genetic instructions enclosed inside human DNA. The project began with the end of several years of work supported by the United States Department of Energy (DoE). It has been reported that the \$3-billion project was founded in 1990 by the DoE and the US National Institutes of Health. In addition to the United States, other countries also took part in the HGP, including the United Kingdom, France, Germany, Japan, China, and India. The team of scientists worked hard over the years and drafted a proposal for the genome project and the final sequencing of the human genome was done in 2006. Although the objective of the HGP is to understand the genetic organization of the human genome, the project has worked with other nonmammalian organisms.

1.4.2.1 Significance of the genome project

The reason for starting the HGP was to understand the role of genes in the development of diseases. There are reports that suggest more than 3000 genetic disorders known to be caused by genetic mutations. With the current treatment modalities, these genetic disorders cannot be cured without knowing the real cause. And to know the cause we have to know the role of genes in the diseases. Recent efforts have been made to find out the causes of cancer with genetic tools, but not much success was achieved. It has been recommended that information gained from the HGP would help to understand the genetic cause of the devastating illnesses, which include Parkinson's disease, schizophrenia, or Alzheimer's disease.

The genetic mutations play a role in many genetic diseases that include heart disease, diabetes, immune system disorders, and congenital defects. These diseases are thought to be the consequence from complex collaborations between genes and environmental factors. When genes for diseases have been identified, researchers can study how environmental factors, food, drugs, or pollutants can influence those genes. The location of the gene is important in identifying the type of protein which is produced by a particular gene. It has been reported that understanding the mechanism of a genetic disease is an important step in curing genetic diseases. It has been suggested that one day it may be possible to treat genetic diseases by gene therapy. Besides therapeutic applications, the information gained from the HGP can help to know the reason for the pluripotency nature of ESCs and how these ESCs can be differentiated into many different specialized cells such as muscle cell, neural cells, or hepatocytes.

1.4.3 RNA interference technology

The RNA interference (RNAi) is a natural process that cells dictate to turn down or go to a silent state; such activity cell is regulated by a specific gene known as RNAi. The RNAi technology provides excellent tools to study the role specific gene in the development, causes, and progression of particular diseases, and has taken the biomedical community by storm. It has been reported that RNAi was first noticed in the plant *Petunia* when plant biologists tried to develop the purple color of the flower by introducing a pigment-producing gene. Surprisingly, the gene which was introduced to intensify color in the plants was found to suppress the color. In the end the resulting flowers developed white patches or became completely white. Surprisingly, a few years later another group of researchers observed a similar kind of gene-silencing effect in *Caenorhabditis elegans*. Later on, it has been reported that the gene-silencing effect is caused by the presence of double-stranded RNA, and this double-stranded RNA is normally not found in healthy cells.

RNAi technology has been in use in various fields of biotechnology, particularly in the food plant engineering that produces lower levels of natural toxins.

No plant that uses RNAi technology has yet passed the experimental stage; however, research work has been known to effectively reduce the allergen levels in tomato plants and also is known to cut the cancer-causing agents in tobacco plants. Also, other plant characters that have also been bioengineered include the production of nonnarcotic natural products by using the opium plant, development of resistance to common plant viruses, and protection of plants with dietary antioxidants. Interestingly, bioengineered plants such as *FlavrSavr* tomatoes and two cultivars of *ring-spot*-resistant papaya were originally developed by employing antisense technology.

One of the pronounced applications of RNAi technology is its application in medicine. Over the past few years, efforts have been made to understand RNAi's role in normal and diseased cells, and also to use the RNAi technology for use in medical therapies. It

has been suggested that human disease progression can be blocked by using RNAi-based therapies to turn down the activity of genes. Cancer, for example, is frequently caused by over-excited genes in the cells, and retarding their activities could stop the disease progression. Over the last few years, several pharmaceutical companies are using RNAi-based therapies to treat for various forms of cancer. In addition, viral infections can also be treated using RNAi-based therapies and this can be done by reducing the activity of key viral genes. It has been shown in the laboratory that human cells have successfully stopped the growth of HIV, polio, hepatitis C, and other viruses in human cell culture and RNAi-based therapies against HIV are under clinical trial stages. Moreover, the importance of RNAi technology has some beneficial effects in finding out the cause of the disease. Using RNAi technology, the activity of a particular gene can be knocked down which will help us to understand its role in the disease development and progression. For many years, researchers have been studying how proteins regulate gene activity. Now with the help of RNAi technology, it would be possible to discover the role of proteins in gene regulation.

1.4.4 Phage therapy

Phage therapy is generally to treat pathogenic infections caused by microorganisms and bacteriophages. Phages are basically viruses that enter bacterial cells and disturb bacterial metabolism causing the bacterium to lyse. It has been reported that phage therapy is very effective in special clinical conditions and is known to have some unique advantages over antibiotic treatments. Unlike antibiotics, phage therapies have special advantages for localized use in humans because they infiltrate deeper in the infected area and remove the infection from the source. Another interesting aspect of bacteriophage is that these phages stop reproducing once the specific bacteria they target are destroyed. It has been reported that phages do not develop secondary resistance, which happens quite often in antibiotic treatments. With the increasing incidence of antibiotic-resistant bacteria in humans, there is a need to apply phages in treating various kinds' of infections. In addition, phage therapy has many potential applications that include medicine, dentistry, veterinary science, and agricultural science. In addition, bacteriophages are found to be much more specific than antibiotics, and this bacteriophage do not cause any harmful effects on the host organism such as human, animal, or plant, but instead maintains a healthy relationship with beneficial bacteria in the body.

Over the last few years, it has been reported that phages are being used to treat bacterial infections in the patients and especially in those patients who do not respond to antibiotics. It has been found that these phage therapies tend to be more successful than antibiotics because there is a biofilm covered by a polysaccharide layer, which antibiotics typically cannot penetrate. In the West, no therapies are currently authorized for use on humans, although phages for killing food poisoning bacteria such as *Listeria* are now in use. On the contrary, there are some disadvantages of phage therapy because a phage will only kill a bacterium if it is a match to the specific strain of the bacterium and it will not kill non-specific strain of bacterium.

1.4.5 Recombinant DNA technology

Recombinant DNA (rDNA) technology is one of the most sought-after technologies that has completely revolutionized the current treatment modalities, especially the use of humanized insulin for diabetes treatment. The rDNA technology soon to be developed can also be used in the treatment of diseases such as diabetes, genetic disorders, cystic

fibrosis, cancer, and sickle cell anemia. The organisms that have been developed by using rDNA technology will be used to produce new vaccines, monoclonal antibodies, enzymes, and hormones. It has been suggested that biotechnology be used to enhance breeding in plants and animals. In addition, rDNA technology can also be used to develop disease and herbicide-resistant plants, disease-resistant animals, seedless fruits, and quick-growing chickens.

1.4.6 *Biochips*

With the advent of information technology, it is possible to store biological information in a chip format which is called as a biochip. Biochip is a chip made of metal and designed to work inside the human body to treat and to diagnose the disease. There are various applications of biochips, which include biochips that can be implanted in the body and used for delivering precise amounts of drugs to the affected organs. Biochips can also be used as biosensors to monitor levels of enzymes, monoclonal antibodies, proteins in the human body, to detect hazardous substances, and to monitor blood components in the body.

1.4.7 *Gene therapy*

To treat genetic disorders, the default or dysfunctional gene can either be replaced with a new gene or repaired with gene therapy. In brief, the gene therapy involves correcting defects in genes and in this process a normal/healthy gene is introduced to replace a defective gene. Gene therapy is still under development stages and various clinical trials are underway around the world. Its success will be based on the successful cure of genetic diseases by gene therapy.

1.4.8 *Liposome-based drug delivery*

One of the major challenges of current drug therapy is to successfully transport the drugs to targeted sites in the human body. In recent times researchers have made efforts to develop a system to accurately and precisely release the drugs at the sites and one of the approaches is to transport the drug using liposomes as a vehicle. Liposomes are basically tiny vesicles made out of the same material as the human cell membrane. It has been suggested that liposomes can be packed with drug molecules and be used to deliver drugs in a precise and accurate manner to the affected regions of cells, especially in the treatment of cancer, without affecting the surrounding healthy cells.

1.4.9 *Bionanotechnology*

Bionanotechnology is a term that refers to the intersection of nanotechnology and biology. This discipline helps to indicate the merger of biological research in various fields of nanotechnology. The concepts that are enhanced through nanobiology include: nanodevices, nanoparticles, and nanoscale that occurs within the discipline of nanotechnology. Moreover, this technical method in biology allows scientists to imagine and create systems that can be used for biological research. Biologically inspired nanotechnology uses biological systems as the inspiration for technologies not yet created. The most important objectives that are frequently found in nanobiology involve applying nanotools to relevant medical or biological problems and refining these applications. Moreover, developing new tools for the medical and biological fields is another primary objective in nanotechnology.

Interestingly, new nanotools are often made by refining the applications of the nanotools that are already being used. The imaging of native biomolecules, biological membranes, and tissues is also a major topic for the nanobiology researchers. Other topics concerning nanobiology include the use of cantilever array sensors and the application of nanophotonics for manipulating molecular processes in living cells.

Recently, the use of microorganisms to synthesize functional nanoparticles have been of great interest. Microorganisms can change the oxidation state of metals. Moreover, these microbial processes have opened up new opportunities for us to explore novel applications, for example, the biosynthesis of metal nanomaterials. In contrast to chemical and physical methods, microbial processes for synthesizing nanomaterials can be achieved in aqueous phases under gentle and environmentally benign conditions. This approach has become an attractive focus on current green bionanotechnology research toward sustainable development.

The applications of bionanotechnology are extremely widespread and nanobiotechnology is best described as helping modern medicine progress from treating symptoms to generating cures and regenerating biological tissues. Three American patients have received whole cultured bladders with the help of doctors who use nanobiology techniques in their practice. Also, it has been demonstrated in animal studies that a uterus can be grown outside the body and then placed in the body in order to produce a baby. Furthermore, there is also funding for research into allowing people to have new limbs without having to resort to prosthesis. Artificial proteins might also become available to manufacture without the need for harsh chemicals and expensive machines. It has even been surmised that by 2055, computers may be made out of biochemical and organic salts. Another example of current nanobiotechnological research involves nanospheres coated with fluorescent polymers. Moreover, investigators are seeking to design polymers whose fluorescence are quenched when they encounter specific molecules. Different polymers would detect different metabolites. Interestingly, the polymer-coated spheres could become part of new biological assays, and the technology might someday lead to the particles which could be introduced into the human body to track down metabolites associated with tumors and other health problems. Another example, from a different perspective, would be an evaluation and therapy at the nanoscopic level, that is, the treatment of nanobacteria (25–200 nm sized) as is done by NanoBiotech Pharma.

Despite the fact that biological systems are inherently nano in scale, nanoscience must merge with biology in order to deliver biomacromolecules and molecular machines that are similar to the human body or organ. In the twenty-first century, scientists have developed the technology to artificially tap into nanobiology. This process is best described as organic merging with synthetic. Interestingly, colonies of live neurons can live together on a biochip device. The self-assembling nanotubes have the ability to be used as a structural system as they would be composed together with rhodopsins, which would help the optical computing process and also help with the storage of biological materials. The most fascinating aspects would be of DNA as the software for all living things, which can be used as a structural proteomics system—a logical component of molecular computing.

1.5 Summary

The term biotechnology generally refers to the integration of technology or engineering knowledge in biological science. The fundamental applications of biotechnology are to produce arrays of products which are beneficial for human consumptions and also for making our environment healthy and pollution free. In particular, the human body is

very critical and requires proper care, diagnosis, and treatment. There are many diseases (malaria, typhoid, cold flu, fever, etc.) which are being treated by using synthetically designed medicines (tablets, capsules, syrups, etc.), but there are many diseases (diabetes, genetic disorders) that cannot be treated with synthetically designed medicines and require biotechnological interventions like insulin and gene therapy. Medical biotechnology primarily deals with providing solutions to major human diseases either in the form of diagnostic kits or in the form of vaccines, antibiotics, monoclonal antibodies, cell-based therapy, or gene therapy. One of the best examples of modern medical biotechnology is the development of antibiotics and vaccines, which in fact is experienced by almost every human being.

1.6 Scholar's achievement

Sir Alexander Fleming: Sir Alexander Fleming, FRSE, FRS, FRCS (Eng) (August 6, 1881 to March 11, 1955) was a Scottish biologist, pharmacologist, and botanist. He wrote many articles on bacteriology, immunology, and chemotherapy. His best-known discoveries are the enzyme lysozyme in 1923 and the antibiotic substance penicillin from the mold *Penicillium notatum* in 1928, for which he shared the Nobel Prize in Physiology or Medicine in 1945 with Howard Florey and Ernst Boris Chain.

James Watson and Francis Crick: Francis Crick and James D. Watson, the two scientists who discovered the structure of DNA in 1953. James Dewey Watson, KBE, ForMemRS (born April 6, 1928), is an American molecular biologist, geneticist, and zoologist, best known as a co-discoverer of the structure of DNA in 1953 by Francis Crick. Watson, Crick, and Maurice Wilkins were awarded the 1962 Nobel Prize in Physiology or Medicine "for their discoveries concerning the molecular structure of nucleic acids and its significance for information transfer in living material." Francis Harry Compton Crick, OM, FRS (June 8, 1916 to July 28, 2004) was an English molecular biologist, biophysicist, and a neuroscientist.

Edward Jenner: Edward Anthony Jenner, FRS (May 17, 1749 to January 26, 1823) was an English physician and scientist from Berkeley, Gloucestershire, who was the pioneer of smallpox vaccine. He is often called "the father of immunology," and his work is said to have "saved more lives than the work of any other man."

Sir Louis Pasteur: Louis Pasteur was a French chemist and microbiologist who was one of the most important founders of medical microbiology. He is remembered for his remarkable breakthroughs in the causes and prevention of diseases. His discoveries reduced mortality from puerperal fever, and he created the first vaccines for rabies and anthrax. His experiments supported the germ theory of disease. He was best known to the general public for inventing a method to treat milk and wine in order to prevent it from causing sickness, a process that came to be called pasteurization. He is regarded as one of the three main founders of microbiology, together with Ferdinand Cohn and Robert Koch. He worked chiefly in Paris.

Paul Ehrlich: Paul Ehrlich (March 14, 1854 to August 20, 1915) was a German physician and scientist who worked in the fields of hematology, immunology, and chemotherapy. He invented the precursor technique to Gram staining bacteria, and the methods he developed for staining tissue made it possible to distinguish between different types of blood cells, which led to the capability to diagnose numerous blood diseases. His laboratory discovered Arsphenamine (Salvarsan), the first effective medicinal treatment for syphilis, thereby initiating and also naming the concept of chemotherapy. Ehrlich popularized the concept of a "magic bullet." He also made a decisive contribution to the development of an antiserum to combat diphtheria and conceived a methodology for standardizing

therapeutic serums. In 1908 he received a Nobel Prize in Physiology or Medicine for his contributions to immunology.

1.7 Knowledge builder

PCR: Polymerase chain reaction (PCR) enables researchers to produce billions of copies of a specific DNA sequence as shown in the picture. This automated process bypasses the need to use bacteria for amplifying DNA. Developed in 1983 by Kary Mullis, PCR is now a common and often indispensable technique used in medical and biological research labs for a variety of applications. The PCR technique was patented by Kary Mullis and assigned to Cetus Corporation, where Mullis worked when he invented the technique in 1983. The PCR techniques have mainly used to study DNA cloning for sequencing, DNA-based phylogeny, or functional analysis of genes; the diagnosis of hereditary diseases; the identification of genetic fingerprints (used in forensic sciences and paternity testing); and the detection and diagnosis of infectious diseases. In 1993, Mullis was awarded the Nobel Prize in Chemistry along with Michael Smith for his work on PCR.

FISH: Fluorescence in situ hybridization (FISH is a cytogenetic technique to detect and localize the presence or absence of specific DNA sequences on chromosomes. FISH uses fluorescent probes that bind to only those parts of the chromosome with which they show a high degree of sequence complementarity. FISH is frequently used for finding specific topographies in DNA for use in genetic counseling, medicine, and species identification. FISH can also be used to detect and localize specific RNA targets in tumor cells, and pathological tissue samples.

Microarray: A microarray, also known as a DNA chip or biochip, is basically a collection of microscopic DNA spots attached to a solid surface (see picture). Scientists use DNA microarrays to measure the expression levels of large numbers of genes simultaneously or to genotype multiple regions of a genome. The gene expression can be used to measure the difference between the normal and diseased tissues or samples to be able to find out the role of different genes in the development of disease.

Gram-positive bacteria: Gram-positive bacteria are those that are stained dark blue or violet by Gram staining. Gram-positive organisms are able to retain the crystal violet stain because of the high amount of peptidoglycan in the cell wall. The examples of Gram-positive bacteria are *Streptococcus* and *Staphylococcus*.

Gram-negative bacteria: Gram-negative bacteria are bacteria that do not retain the crystal violet dye in the Gram staining procedure because these bacteria contain an outer membrane. The Proteobacteria are a major group of Gram-negative bacteria, including *Escherichia coli*, *Salmonella*, *Shigella*, and other Enterobacteriaceae, *Pseudomonas*, *Moraxella*, *Helicobacter*, *Stenotrophomonas*, *Bdellovibrio*, acetic acid bacteria, *Legionella* and numerous others.

Micro-array technique: A DNA microarray (also commonly known as a DNA chip or biochip) is a collection of microscopic DNA spots attached to a solid surface. Scientists use DNA microarrays to measure the expression levels of large numbers of genes simultaneously or to genotype multiple regions of a genome. Each DNA spot contains picomoles (10 – 12 moles) of a specific DNA sequence, known as probes (or reporters or oligos). These can be a short section of a gene or other DNA element that is used to hybridize a cDNA or CRNA (also called antisense RNA) sample (called target) under high-stringency conditions. Probe–target hybridization is usually detected and quantified by detection of fluorescence-, silver-, or chemiluminescence-labeled targets to determine relative abundance of nucleic acid sequences in the target.

Recombinant DNA technology: Recombinant DNA (rDNA) molecules are DNA sequences that result from the use of laboratory methods (molecular cloning) to bring together genetic material from multiple sources, creating sequences that would not otherwise be found in biological organisms. Recombinant DNA is possible because DNA molecules from all organisms share the same chemical structure; they differ only in the sequence of nucleotides within that identical overall structure. Consequently, when DNA from a foreign source links to host sequences that can drive DNA replication, and then is introduced into a host organism, the foreign DNA is replicated along with the host DNA.

Hybridoma technology: Hybridoma technology is a technology of forming hybrid cell lines (called hybridomas) by fusing a specific antibody-producing B cell with a myeloma (B cell cancer) cell that is selected for its ability to grow in tissue culture and for an absence of antibody chain synthesis. The antibodies produced by the hybridoma are all of a single specificity and are, therefore, monoclonal antibodies (in contrast to polyclonal antibodies). The production of monoclonal antibodies was invented by Cesar Milstein and Georges J. F. Köhler in 1975.

Biocompatible materials: A biocompatible material (sometimes shortened to biomaterial) is a synthetic or natural material used to replace part of a living system or to function in intimate contact with living tissue. Biocompatible materials are intended to interface with biological systems to evaluate, treat, augment, or replace any tissue, organ, or function of the body. Biomaterials are usually nonviable, but may also be viable.

Autologous cell transplantation: Autologous stem cell transplantation is a medical procedure in which stem cells (cells from which other cells of the same type develop) are removed, stored, and later given back to the same person. Though most frequently performed with hematopoietic stem cells (blood forming), cardiac cells have also been used successfully to repair damage caused by heart attacks.

FDA: The Food and Drug Administration (FDA or USFDA) is a regulatory agency of the United States Department of Health and Human Services, belonging to the US federal executive departments. The FDA is responsible for protecting and promoting public health through the regulation and supervision of food safety, tobacco products, dietary supplements, prescription and over-the-counter pharmaceutical drugs, vaccines, biopharmaceuticals, blood transfusions, medical devices, electromagnetic radiation-emitting devices, and veterinary products.

Geron Corporation: Geron Corporation is a biotechnology company located in Menlo Park, California, USA, that focuses on the development and commercialization of products in three specific areas: therapeutic products for cancer treatment; pharmaceuticals that activate telomerase in tissues impacted by cell aging, injury, or degenerative diseases; and cell-based therapies derived from human ESCs for treatment of various chronic diseases.

Further reading

- Allen R, Millgate A, Chitty J, Thisleton J et al. 2004. RNAi-mediated replacement of morphine with the nonnarcotic alkaloid reticuline in opium poppy. *Nat Biotechnol* 22 (12): 1559–1566. doi:10.1038/nbt1033. PMID 15543134.
- Altman J and Das GD 1965. Autoradiographic and histological evidence of postnatal hippocampal neurogenesis in rats. *J Compar Neurol* 124 (3): 319–335. doi:10.1002/cne.901240303. PMID 5861717.
- Alvarez-Buylla A, Seri B, and Doetsch F 2002. Identification of neural stem cells in the adult vertebrate brain. *Brain Res Bull* 57 (6): 751–758. doi:10.1016/S0361-9230(01)00770-5. PMID 12031271.
- Bains WE 1993. *Biotechnology from A to Z*. Oxford, UK: Oxford University Press.

- Barnhart BJ 1989. DOE Human Genome Program. *Human Genome Quarterly* 1: 1. http://www.ornl.gov/sci/techresources/Human_Genome/publicat/hgn/v1n1/01doehgp.html (retrieved 2005-02-03).
- Barrilleaux B, Phinney DG, Prockop DJ, and O'Connor KC 2006. Review: Ex vivo engineering of living tissues with adult stem cells. *Tissue Eng* 12 (11): 3007–3019. doi:10.1089/ten.2006.12.3007. PMID 17518617.
- Beachy PA, Karhadkar SS, and Berman DM 2004. Tissue repair and stem cell renewal in carcinogenesis. *Nature* 432 (7015): 324–331. doi:10.1038/nature03100. PMID 15549094.
- Benton D 1996. Bioinformatics—Principles and potentials of a new multidisciplinary tool. *Trends Biotechnol* 14:261–72.
- Bjornson CR, Rietze RL, Reynolds BA et al. 1999. Turning brain into blood: A hematopoietic fate adopted by adult neural stem cells in vivo. *Science* 283 (5401): 534–537. doi:10.1126/science.283.5401.534. PMID 9915700.
- ter Brake O, Westerink JT, and Berkhout B. 2010. Lentiviral vector engineering for anti-HIV RNAi gene therapy. *Methods Mol Biol* 614: 201–213. doi: 10.1007/978-1-60761-533-0_14.
- Bull ND and Bartlett PF 2005. The adult mouse hippocampal progenitor is neurogenic but not a stem cell. *J Neurosci* 25 (47): 10815–10821. doi:10.1523/JNEUROSCI.3249-05.2005. PMID 16306394.
- Cavaliere D, McGovern PE, Hart DL, Mortimer R, and Polsinelli M 2003. Evidence for *S. cerevisiae* fermentation in ancient wine. *J Mol Evol* 57: S226–S232.
- Centeno CJ, Busse D, Kisiday J, Keohan C et al. 2008a. Increased knee cartilage volume in degenerative joint disease using percutaneously implanted, autologous mesenchymal stem cells. *Pain Phys* 11 (3): 343–353. PMID 18523506. http://www.painphysicianjournal.com/linkout_vw.php?issn=1533-3159&vol=11&page=343.
- Centeno CJ, Busse D, Kisiday J, Keohan C et al. 2008b. Regeneration of meniscus cartilage in a knee treated with percutaneous implanted autologous mesenchymal stem cells. *Med Hypoth* 71 (6): 900–908. doi:10.1016/j.mehy.2008.06.042. PMID 18786777.
- Chaudhary PM and Roninson IB 1991. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. *Cell* 66 (1): 85–94. doi:10.1016/0092-8674(91)90141-K. PMID 1712673.
- Chiang C, Wang J, Jan F, Yeh S, and Gonsalves D. 2001. Comparative reactions of recombinant papaya ringspot viruses with chimeric coat protein (CP) genes and wild-type viruses on CP-transgenic papaya. *J Gen Virol* 82 (Part 11): 2827–2836. PMID 11602796.
- Cogle CR, Guthrie SM, Sanders RC, Allen WL, Scott EW, and Petersen BE 2003. An overview of stem cell research and regulatory issues. *Mayo Clinic Proc* 78 (8): 993–1003. doi:10.4065/78.8.993. PMID 12911047.
- Covey S, Al-Kaff N, Langara A, and Turner D 1997. Plants combat infection by gene silencing. *Nature* 385: 781–782. doi:10.1038/385781a0.
- DeLisi C. 2001. Genomes: 15 years later a perspective by Charles DeLisi, HGP Pioneer. *Human Genome News* 11: 3–4. <http://genome.gsc.riken.go.jp/hgmis/publicat/hgn/v11n3/05delisi.html> (retrieved 2005-02-03).
- Dirar H. 1993. *The Indigenous Fermented Foods of the Sudan: A Study in African Food and Nutrition*. UK: CAB International
- Doetsch F, Petreanu L, Caille I, Garcia-Verdugo JM, and Alvarez-Buylla A 2002. EGF converts transit-amplifying neurogenic precursors in the adult brain into multipotent stem cells. *Neuron* 36 (6): 1021–1034. doi:10.1016/S0896-6273(02)01133-9. PMID 12495619.
- Dontu G, Jackson KW, McNicholas E, Kawamura MJ et al. 2004. Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells. *Breast Cancer Res* 6 (6): R605–R615. doi:10.1186/bcr920. PMID 15535842.
- Ecker JR and Davis RW 1986. Inhibition of gene expression in plant cells by expression of antisense RNA. *Proc Natl Acad Sci USA* 83 (15): 5372–5376. doi:10.1073/pnas.83.15.5372. PMID 16593734.
- Fermented fruits and vegetables. 2007. A global perspective. *FAO Agricultural Services Bulletins—134*. <http://www.fao.org/docrep/x0560e/x0560e05.htm> (retrieved on 2007-01-28).
- Fischer UM, Harting MT, Jimenez F et al. June 2009. Pulmonary passage is a major obstacle for intravenous stem cell delivery: The pulmonary first-pass effect. *Stem Cells Dev* 18 (5): 683–692. doi:10.1089/scd.2008.0253. PMID 19099374.

- Gardner RL March 2002. Stem cells: Potency, plasticity and public perception. *J Anat* 200 (Part 3): 277–282. doi:10.1046/j.1469-7580.2002.00029.x. PMID 12033732.
- Gavilano L, Coleman N, Burnley L, Bowman M, Kalengamaliro N et al. 2006. Genetic engineering of *Nicotiana tabacum* for reduced normicotine content. *J Agric Food Chem* 54 (24): 9071–9078. doi:10.1021/jf0610458. PMID 17117792.
- Gimble JM, Katz AJ, and Bunnell BA 2007. Adipose-derived stem cells for regenerative medicine. *Circ Res* 100 (9): 1249–1260. doi:10.1161/01.RES.0000265074.83288.09. PMID 17495232.
- Guo S and Kemphues K 1995. Par-1, a gene required for establishing polarity in *C. elegans* embryos, encodes a putative Ser/Thr kinase that is asymmetrically distributed. *Cell* 81 (4): 611–620. doi:10.1016/0092-8674(95)90082-9. PMID 7758115.
- Kruger GM, Mosher JT, Bixby S, Joseph N et al. 2002. Neural crest stem cells persist in the adult gut but undergo changes in self-renewal, neuronal subtype potential, and factor responsiveness. *Neuron* 35 (4): 657–669. doi:10.1016/S0896-6273(02)00827-9. PMID 12194866.
- Le L, Lorenz Y, Scheurer S, Fötisch K, Enrique E, Bartra J et al. 2006. Design of tomato fruits with reduced allergenicity by dsRNAi-mediated inhibition of ns-LTP (*Lyc e 3*) expression. *Plant Biotechnol J* 4 (2): 231–242. doi:10.1111/j.1467-7652.2005.00175.x. PMID 17177799.
- Lewis PD 1968. Mitotic activity in the primate subependymal layer and the genesis of gliomas. *Nature* 217 (5132): 974–975. doi:10.1038/217974a0. PMID 4966809.
- Liu S, Dontu G, and Wicha MS 2005. Mammary stem cells, self-renewal pathways, and carcinogenesis. *Breast Cancer Res* 7 (3): 86–95. doi:10.1186/bcr1021. PMID 15987436.
- Maggie F (Reuters) 2006. U.S. firm says it made stem cells from human testes. *Washington Post*. <http://www.washingtonpost.com/wp-dyn/content/article/2006/04/01/AR2006040101145.html>.
- Marshall GP, Laywell ED, Zheng T, Steindler DA, and Scott EW 2006. In vitro-derived neural stem cells function as neural progenitors without the capacity for self-renewal. *Stem Cells* 24 (3): 731–738. doi:10.1634/stemcells.2005-0245. PMID 16339644.
- Matzke MA and Matzke AJM 2004. Planting the seeds of a new paradigm. *PLoS Biol* 2 (5): e133. doi:10.1371/journal.pbio.0020133. PMID 15138502.
- Mol JNM and van der Krol AR 1991. *Antisense Nucleic Acids and Proteins: Fundamentals and Applications*. pp. 248. New York: Marcel Dekker.
- Murrell W, Féron F, Wetzig A et al. 2005. Multipotent stem cells from adult olfactory mucosa. *Dev Dynam* 233 (2): 496–515. doi:10.1002/dvdy.20360. PMID 15782416.
- Napoli C, Lemieux C, and Jorgensen R 1990. Introduction of a chimeric chalcone synthase gene into *Petunia* results in reversible co-suppression of homologous genes in trans. *Plant Cell* 2 (4): 279–289. doi:10.1105/tpc.2.4.279. PMID 12354959.
- Niggeweg R, Michael A, and Martin C 2004. Engineering plants with increased levels of the antioxidant chlorogenic acid. *Nat Biotechnol* 22 (6): 746–754. doi:10.1038/nbt966. PMID 15107863.
- Nora S 2008. A source of men's stem cells—Stem cells from human testes could be used for personalized medicine. *Technol Rev*. <http://www.technologyreview.com/biomedicine/21487/>.
- Pederson RA 1999. Embryonic stem cells for medicine. *Sci Am* 280: 68–73.
- Phinney DG and Prockop DJ 2007. Concise review: Mesenchymal stem/multipotent stromal cells: The state of transdifferentiation and modes of tissue repair—Current views. *Stem Cells* 25 (11): 2896–2902. doi:10.1634/stemcells.2007-0637. PMID 17901396.
- Ratajczak MZ, Machalinski B, Wojakowski W, Ratajczak J, and Kucia M 2007. A hypothesis for an embryonic origin of pluripotent Oct-4(+) stem cells in adult bone marrow and other tissues. *Leukemia* 21 (5): 860–867. doi:10.1038/sj.leu.2404630. PMID 17344915.
- Ratcliff F, Harrison B, and Baulcombe D 1997. A similarity between viral defense and gene silencing in plants. *Science* 276: 1558–1560. doi:10.1126/science.276.5318.1558.
- Reynolds BA and Weiss S 1992. Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. *Science* 255 (5052): 1707–1710. doi:10.1126/science.1553558. PMID 1553558.
- Rick W 2006. Embryonic stem cell success. *Washington Post*. <http://www.washingtonpost.com/wp-dyn/content/article/2006/03/24/AR2006032401721.html>.
- Rob W 2008. *Testicle Stem Cells Become Bone, Muscle in German Experiments*. *Bloomberg*. <http://www.bloomberg.com/apps/news?pid=20601124&sid=aNmiXs8SPp4w&refer=home>.

- Romano N and Macino G 1992. Quelling: Transient inactivation of gene expression in *Neurospora crassa* by transformation with homologous sequences. *Mol Microbiol* 6 (22): 3343–3353. doi:10.1111/j.1365-2958.1992.tb02202.x. PMID 1484489.
- Rose D 2008. Claudia Castillo gets windpipe tailor-made from her own stem cells. *The Times*. London: The Times Newspapers Ltd. http://www.timesonline.co.uk/tol/life_and_style/health/article5183686.ece (retrieved 2008-2011).
- Sanders R and Hiatt W 2005. Tomato transgene structure and silencing. *Nat Biotechnol* 23 (3): 287–289. doi:10.1038/nbt0305-287b. PMID 15765076.
- Shi S, Bartold PM, Miura M, Seo BM, Robey PG, and Gronthos S 2005. The efficacy of mesenchymal stem cells to regenerate and repair dental structures. *Orthod Craniofac Res* 8 (3): 191–199. doi:10.1111/j.1601-6343.2005.00331.x. PMID 16022721.
- Sieber-Blum M and Hu Y 2008. Epidermal neural crest stem cells (EPI-NCSC) and pluripotency. *Stem Cell Rev* 4 (4): 256–260. doi:10.1007/s12015-008-9042-0. PMID 18712509.
- Siritunga D and Sayre R 2003. Generation of cyanogen-free transgenic cassava. *Planta* 217 (3): 367–373. doi:10.1007/s00425-003-1005-8. PMID 14520563.
- Sugihara TF 1985. Microbiology of breadmaking. In *Microbiology of Fermented Foods*, ed. B.J.B. Wood, UK: Elsevier Applied Science Publishers.
- Sunilkumar G, Campbell L, Puckhaber L, Stipanovic R, and Rathore K 2006. Engineering cotton seed for use in human nutrition by tissue-specific reduction of toxic gossypol. *Proc Natl Acad Sci USA* 103 (48): 18054–18059. doi:10.1073/pnas.0605389103. PMID 17110445.
- Takahashi K and Yamanaka S 2006. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell* 126 (4): 663–676. doi:10.1016/j.cell.2006.07.024. PMID 16904174.
- Van Blokland R, Van der Geest N et al. 1994. Transgene-mediated suppression of chalcone synthase expression in *Petunia hybrida* results from an increase in RNA turnover. *Plant J* 6: 861–877. doi:10.1046/j.1365-313X.1994.6060861.x/abs/. <http://www.blackwell-synergy.com/links/doi/10.1046/j.1365-313X.1994.6060861.x/abs/>.
- Wakitani S, Nawata M, Tensho K, Okabe T, Machida H, and Ohgushi H 2007. Repair of articular cartilage defects in the patello-femoral joint with autologous bone marrow mesenchymal cell transplantation: Three case reports involving nine defects in five knees. *J Tissue Eng Regen Med* 1 (1): 74–79. doi:10.1002/term.8. PMID 18038395.
- Zadeh A and Foster G 2004. Transgenic resistance to tobacco ringspot virus. *Acta Virol* 48 (3): 145–152. PMID 15595207.

BIOTECHNOLOGY IN MEDICAL SCIENCES

As the field of medical biotechnology grows with new products and discoveries, so does the need for a holistic view of biotechnology in medicine. **Biotechnology in Medical Sciences** fulfills that need by delivering a detailed overview of medical biotechnology as it relates to human diseases and epidemiology, bacteriology and antibiotics, virology and vaccines, immunology and monoclonal antibodies, recombinant DNA technology and therapeutic proteins, stem cell technology, tissue engineering, molecular diagnostics and forensic science, gene therapy, synthetic biology and nanomedicine, pharmacogenomics, bioethics, biobusiness and intellectual property rights, and career opportunities.

Organized to follow the chronology of major medical biotechnology research, breakthroughs, and events, this first-of-its-kind text:

- Covers all aspects of medical biotechnology, from labs to clinics and basic to advanced applications
- Describes historical perspectives and modern discoveries in medical biotechnology
- Explains how various biotechnology products are used to treat and prevent disease
- Discusses the tools and techniques currently employed in medical biotechnology
- Includes a bibliography at the end of each chapter to encourage further study

Complete with colorful illustrations and examples, **Biotechnology in Medical Sciences** provides a comprehensive yet accessible treatment of this growing field.



CRC Press

Taylor & Francis Group
an **informa** business

www.crcpress.com

6000 Broken Sound Parkway, NW
Suite 300, Boca Raton, FL 33487
711 Third Avenue
New York, NY 10017
2 Park Square, Milton Park
Abingdon, Oxon OX14 4RN, UK

K22340

